KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2016 - 2025)

Vertex Pharmaceuticals has reported Cash from Investing Activities over the past 17 years, most recently at -$288.1 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$288.1 million for Q4 2025, up 64.95% from a year ago — trailing twelve months through Dec 2025 was -$945.4 million (up 74.92% YoY), and the annual figure for FY2025 was -$945.4 million, up 74.92%.
  • Cash from Investing Activities for Q4 2025 was -$288.1 million at Vertex Pharmaceuticals, down from -$117.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for VRTX hit a ceiling of $175.6 million in Q4 2022 and a floor of -$2.1 billion in Q1 2024.
  • Median Cash from Investing Activities over the past 5 years was -$211.0 million (2021), compared with a mean of -$426.0 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 231.04% in 2022 and later tumbled 3495.29% in 2023.
  • Vertex Pharmaceuticals' Cash from Investing Activities stood at -$134.0 million in 2021, then soared by 231.04% to $175.6 million in 2022, then tumbled by 604.84% to -$886.5 million in 2023, then grew by 7.29% to -$821.9 million in 2024, then surged by 64.95% to -$288.1 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$288.1 million (Q4 2025), -$117.0 million (Q3 2025), and -$484.5 million (Q2 2025) per Business Quant data.